Breaking News Instant updates and real-time market news.

AMAG

Amag Pharmaceuticals

$11.88

0.3 (2.59%)

07:09
05/07/19
05/07
07:09
05/07/19
07:09

Amag Pharmaceuticals sees FY19 revenue $365M-$415M, consensus $369.17M

  • 07

    May

  • 07

    May

  • 16

    May

  • 23

    Jun

AMAG Amag Pharmaceuticals
$11.88

0.3 (2.59%)

02/07/19
PIPR
02/07/19
NO CHANGE
PIPR
Neutral
Piper maintains 'cautious stance' on Amag, still sees meaningful risk
After Amag Pharmaceuticals reported what Piper Jaffray analyst Christopher Raymond called "an in-line Q418 print" and maintained its FY19 guidance, the analyst said he is maintaining his cautious stance and Neutral rating on the stock. Raymond said a sales force restructuring resulting in 110 positions being eliminated, which he views as the right call, was "the only incremental update [he] gleaned from the call." He believes the sales force cuts are "indicative of the challenges facing the women's health franchise" and still sees risk for next quarter's readout of Makena's confirmatory trial, Raymond tells investors in a post-earnings research note.
03/08/19
PIPR
03/08/19
NO CHANGE
Target $13
PIPR
Neutral
Piper says Makena 'may well be a zero,' cuts Amag target to $13
Piper Jaffray analyst Christopher Raymond lowered his price target for Amag Pharmaceuticals to $13 from $20 and is "incrementally cautious" on the shares after the company announced that Makena's confirmatory study required for full approval failed to meet its co-primary endpoints. With this failure, it's entirely possible that FDA requires the wholesale withdrawal of the entire Makena franchise, Raymond tells investors in a research note titled "Makena May Well Be a Zero After PROLONG Failure." Further, the analyst adds that Amag's annual filing last Friday contained "somewhat concerning disclosures." Among other negative tidbits that included new risk language around continued supply issues as well as autoinjector failures for Makena SubQ, management inserted new, disconcerting risk language about the company's ability to service its debt load, contends Raymond. He keeps a Neutral rating on Amag Pharmaceuticals. The stock in morning trading is down 19%, or $2.57, to $11.16.
03/14/19
CANT
03/14/19
NO CHANGE
Target $14
CANT
Neutral
Amag Pharmaceuticals price target lowered to $14 from $17 at Cantor Fitzgerald
Cantor Fitzgerald analyst Matthew Lillis lowered his price target for Amag Pharmaceuticals to $14 from $17 saying failure of the post-approval Makena trial is a "clear setback for the company." The trial result reinforces the importance of the next 12-18 months for Amag to demonstrate that existing and pipeline assets can adequately replace lost Makena revenue, Lillis tells investors in a research note. He reiterates a Neutral rating on the shares.
03/19/19
RHCO
03/19/19
INITIATION
Target $14
RHCO
Hold
Amag Pharmaceuticals initiated with a Neutral at SunTrust
SunTrust analyst Gregg Gilbert initiated Amag Pharmaceuticals with a Neutral rating and a price target of $14, citing the company's focus to address areas of unmet need, such as "in Women's Healt hand the hospital setting". The analyst believes that the management is "steering the company in the right direction" to diversify its revenue base, but reserves a more constructive rating until more signs of regulatory and commercial execution. Gilbart adds that the "recent news on a negative clinical trial for Makena" is also giving him pause.

TODAY'S FREE FLY STORIES

11:25
05/23/19
05/23
11:25
05/23/19
11:25
General news
Treasury announced $113 B in shorter coupons for auction »

Treasury announced $113 B…

11:25
05/23/19
05/23
11:25
05/23/19
11:25
Conference/Events
Stephens medical devices analyst to hold a group luncheon »

Medical Devices &…

ECA

Encana

$6.05

-0.435 (-6.71%)

11:20
05/23/19
05/23
11:20
05/23/19
11:20
Options
Notable call buy in Encana as shares dip »

Notable call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTOO

T2 Biosystems

$1.88

-0.685 (-26.76%)

11:19
05/23/19
05/23
11:19
05/23/19
11:19
Hot Stocks
T2 Biosystems highlights clinical data at ECCMID, MAD-ID meetings »

T2 Biosystems highlighted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
05/23/19
05/23
11:17
05/23/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
05/23/19
05/23
11:16
05/23/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
05/23/19
05/23
11:15
05/23/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
05/23/19
05/23
11:15
05/23/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

MICT

Micronet Enertec

$0.99

(0.00%)

11:10
05/23/19
05/23
11:10
05/23/19
11:10
Hot Stocks
Micronet Enertec receives two orders totaling $1.3M for SmartHub platform »

MICT announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$19.64

-0.31 (-1.55%)

11:10
05/23/19
05/23
11:10
05/23/19
11:10
Hot Stocks
EQT Corporation files definitive proxy, mails letter to shareholders »

EQT Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTHT

Huazhu Group

$32.60

-1.81 (-5.26%)

11:10
05/23/19
05/23
11:10
05/23/19
11:10
Downgrade
Huazhu Group rating change  »

Huazhu Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

USO

United States Oil Fund

$12.09

-0.66 (-5.18%)

11:10
05/23/19
05/23
11:10
05/23/19
11:10
Options
Customer rolls US Oil ETF puts for 233% gain as oil sells off »

Customer rolls US Oil ETF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$0.00

(0.00%)

, FANG

Diamondback Energy

$104.01

-4.86 (-4.46%)

11:09
05/23/19
05/23
11:09
05/23/19
11:09
Syndicate
Rattler Midstream opens at $18.06, IPO priced at $17.50 per share »

Rattler Midstream (RTLR)…

RTLR

Rattler Midstream

$0.00

(0.00%)

FANG

Diamondback Energy

$104.01

-4.86 (-4.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 23

    May

FCX

Freeport McMoRan

$9.94

-0.11 (-1.09%)

11:05
05/23/19
05/23
11:05
05/23/19
11:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

IBM

IBM

$132.49

-3.53 (-2.60%)

11:04
05/23/19
05/23
11:04
05/23/19
11:04
Hot Stocks
ProcessMap, IBM announce joint initiative to develop IoT solutions »

ProcessMAP and IBM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

11:04
05/23/19
05/23
11:04
05/23/19
11:04
General news
Kansas City Fed Manufacturing Index Level data reported »

May Kansas City Fed…

LB

L Brands

$24.88

0.59 (2.43%)

10:59
05/23/19
05/23
10:59
05/23/19
10:59
On The Fly
Analysts remain cautious on L Brands despite stronger quarter »

Shares of L Brands (LB)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 22

    Aug

IDYA

IDEAYA Biosciences

$0.00

(0.00%)

10:57
05/23/19
05/23
10:57
05/23/19
10:57
Syndicate
Breaking Syndicate news story on IDEAYA Biosciences »

IDEAYA Biosciences opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CNX

CNX Resources

$7.56

-0.26 (-3.32%)

10:50
05/23/19
05/23
10:50
05/23/19
10:50
Options
Size put option block in CNX after calls bought yesterday »

Size put option block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

10:50
05/23/19
05/23
10:50
05/23/19
10:50
General news
Treasury Action: yields have extended lower as Wall Street sinks »

Treasury Action: yields…

AZZ

AZZ Inc.

$43.62

(0.00%)

10:46
05/23/19
05/23
10:46
05/23/19
10:46
Hot Stocks
AZZ Inc. discloses change in independent registered public accounting firm »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$39.97

-0.22 (-0.55%)

10:45
05/23/19
05/23
10:45
05/23/19
10:45
Hot Stocks
GSK to change sales representative incentive program »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
he April U.S. new home sales report beat estimates »

The April U.S. new home…

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
05/23/19
05/23
10:45
05/23/19
10:45
General news
Kansas City Fed Manufacturing Index Level to be reported at 11:00 »

May Kansas City Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.